Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

NCT05435846 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped slow accrual

Conditions

Metastatic Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer

Interventions

DRUG: Capmatinib
DRUG: Trametinib

Sponsor

Collin Blakely

Collaborators

[object Object]